Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.

Zacks Investment Research • Aug 7, 2026

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

Barrons • Aug 7, 2026

Moderna Wavers Despite Hard-Fought FDA Win; Will Its Sprint Restart?

Moderna stock wavered Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva.

Investors Business Daily • Aug 6, 2026

Moderna Stock Climbs on Flu Vaccine Approval

Moderna Inc (NASDAQ:MRNA) is up 3.6% at $58.30 ahead of the open, after the U.S. Food and Drug Administration (FDA) approved the company's mRNA-based seasonal flu vaccine , mFluvis, for adults ages 50 and older.

Schaeffers Research • Aug 6, 2026

FDA Approves First mRNA Flu Vaccine For Older Adults

"Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors. This approval also reflects the ongoing potential of our mRNA platform,” Moderna CEO Stéphane Bancel said.

Forbes • Aug 6, 2026

Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal

Moderna (MRNA) stock made a name for itself during the height of the pandemic, trading as high as $497 five years ago in 2021. Now, shares of the drugmaker sit at $55.12, pivoting lower despite the Food and Drug Administration (FDA) approving the company's flu vaccine.

Forbes • Aug 6, 2026

This new kind of flu shot by Moderna has just been approved by the FDA

The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufacturer, Moderna.The shot, named mFlusiva, is intended for adults who are 50 and older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.Flu vaccines must be updated annually to best match circulating strains of the virus.

Fast Company • Aug 6, 2026

Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine

The U.S. Food and Drug Administration (FDA) on Wednesday approved Moderna Inc.'s (NASDAQ:MRNA) mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.

Benzinga • Aug 6, 2026

Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future

Moderna's mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.

Barrons • Aug 6, 2026

Sandisk, AppLovin, Moderna, and More Stocks That Explain Today's Market

Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market's sky-high expectations.

Barrons • Aug 6, 2026